Fragmented GRS polypeptide and variant thereof, and use thereof
AssigneeNibec Co., Ltd.
InventorsSunghoon Kim, Peter Charles Goughnour
Life of this patent
Estimating the term…
Abstract
The present invention relates to a fragmented GRS polypeptide and a variant thereof, and a use thereof and, more specifically, to: an isolated polypeptide consisting of 8 to 170 consecutive amino acids including amino acids 531 to 538 in the amino acid sequence represented by SEQ ID NO: 1 or a polypeptide consisting of a variant having a sequence homology of 80% or more with the polypeptide; a fusion protein and a complex comprising the polypeptide; a polynucleotide coding for the polypeptide; and a use thereof for the prevention and treatment of neoplastic diseases, the detection of cancer cells, imaging, and drug delivery.
Claims25
A polypeptide comprising SEQ ID NO:
- 7 and 90% or more sequence identity to SEQ ID NO:
- 1, wherein the polypeptide is 25-160 amino acid residues in length and induces apoptosis in cancer cells.
A fusion protein, comprising a GRS peptide fragment and a heterologous fusion partner, wherein the GRS peptide fragment is 8-160 amino acid residues in length and comprises a sequence selected from the group consisting of SEQ ID NO:
- 2 and SEQ ID NO:
- 7.
Dependencies are inferred from the claim text.